Enfortumab Vedotin–Related Cutaneous Adverse Events: Two Cases Highlighting Ring Mitosis and Severity‐Guided Management

Data sharing not applicable to this article as no datasets were generated or analysed during the current study. Figure S1: Clinical course of Case 1. Timeline of enfortumab vedotin (EV) therapy and subsequent cutaneous eruption. CT images demonstrate local recurrence in the left pelvic mass with multiple metastases within Gerota's fascia and para-aortic lymph nodes. Despite dose reduction, disease progression (retroperitoneal mass enlargement) necessitated a switch to gemcitabine plus carboplatin (GCb). The skin eruption improved with topical corticosteroids and did not recur after EV was resumed at a reduced dose. Figure S2: Clinical course of Case 2. Clinical and radiologic course showing partial response of pulmonary metastases under a reduced-dose EV regimen. An erythematous rash developed on Day 6 and evolved to small vesicles by Day 14; improvement followed temporary withdrawal of EV and topical corticosteroid therapy. EV was safely resumed at a reduced frequency, leading to marked regression of both renal pelvic carcinoma and pulmonary lesions without further cutaneous recurrence. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.